Brookline doubles Arcturus Therapeutics PT to $64 from $32

Arcturus Logo

Brookline Capital Markets raised its price target for Arcturus Therapeutics (NASDAQ:ARCT) to $64 from $32, citing positive immunogenicity data for its COVID-19 vaccine. The stock was quoted at $44.88, up $5.65, in afternoon trading on May 11.

Analyst Kumaraguru Raja writes that in preclinical studies, the company’s LUNAR-COV19 vaccine demonstrated evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses.

“This is important as 30% of confirmed COVID-19 Chinese patients failed to develop high neutralizing antibody titers post infection, which suggests the need for cellular response for recovery,” he added.

In addition, Mr. Raja said the LUNAR-COV19 vaccine has the potential to be seroprotective at low doses with cellular and humoral response. “The extremely low dose of messenger-RNA requirement for seroconversion and adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune response indicates a promising vaccine candidate,” he said.

Arcturus also has a manufacturing process to produce multiple large GMP batches of pure RNA and its recent agreement with Catalent for manufacturing LUNAR-COV19, will allow it to treat a larger population, compared with traditional messenger-RNA vaccines, he said.

Mr. Raja said Arcturus’ pre-clinical data are promising and, if replicated in humans, will “lead to a vaccine that would be efficacious at low doses.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.